A pilot program on the benefits of synthetic psilocybin for mental health issues like post-traumatic stress disorder (PTSD) is set to begin this summer at Yale University in New Haven, Connecticut. 

A study cohort will consist of 50 patients, mostly veterans and first responders, who are with mental health concerns like depression and addiction. Participants will take 25 mg of synthetic psilocybin, and after the psychedelic effects wind down, they will discuss issues and progress (or lack thereof) with trained therapists.

Connecticut Post reports that the goal is to fulfill the need for state data that has been lacking, according to state Rep. Michelle Cook (D-Torrington).

“We need to have the data to show that there is documented proof of what that therapy does,” Cook said. “We know that it has some incredible outcomes when it is done right, when it’s done by people that are trained in how to use it for treatment of PTSD and so forth.”

Researchers at Yale have been studying the “psychological, neurobiological, and therapeutic effects of psychedelic substances” like psilocybin for decades..

Using a Schedule 1 drug in a clinical setting creates a set of unique problems, including the inability to use insurance. “Even though it’s a research program, you are treating them clinically. And then, in order to treat them clinically, you need to have malpractice coverage,” said Yale researcher Ben Kelmendi. Kelmendi and his team are about to embark on a first-of-its-kind study, a pilot program at Yale.

Research on the medical benefits of  psilocybin have been severely hampered due to legal restrictions, Kelmendi said. Only certain qualifying conditions are acceptable in this case. PTSD, for instance, is a complex issue that many people fail to treat.

“With veterans, they will not seek treatment right away,” Kelmendi said. “They will start turning to alcohol or other substances, and so that now they have a comorbidity, and that comorbidity—which really is their own way of coping—will exclude them from the study. They are real patients who are actually suffering and who actually need help. They cannot access these medicines because they do not fit that cookie-cutter profile.” 

The impact of PTSD is hard to define as it affects multiple aspects of daily life.

“There is no one scale that actually captures the complexity of one’s daily functional impairment. It’s actually an index of several different scales,” he said. “One is days missed at work, productivity and relationships, just more daily living. I think that is much more important than saying ‘Oh, have your PTSD symptoms improved or not?’”

Participants will take 25 mg of synthetic psilocybin, enough to induce a psychedelic experience, and the therapy is patient-directed. They will be taken in a comfortable space and about six hours later, participants will undergo a psychotherapy session. 

“Twenty-five milligrams would be considered a moderate dose. It’s not a heroic dose necessarily, but it’s a psychoactive dose, for sure,” Kelmendi said. “The non-directive supportive psychotherapy is to be done after the dosing rather than during the dosing.”

The Many Potential Health Benefits of Psilocybin 

The Yale Program for Psychedelic Science supports this goal with several currently active studies on psilocybin. These include studies on Obsessive Compulsive Disorder (OCD), Major Depressive Disorder (MDD), cluster headaches, post-traumatic headaches, and migraines. Kelmendi is working on several of them.A 2022 report published by a working group under the direction of the Connecticut Department of Mental Health and Addiction Services, was clear about the potential of psilocybin in therapeutic medicine. 

Even people who don’t necessarily intend to gain benefits for mental health from psilocybin are still benefitting, a separate study suggests. A study published last September found that using psilocybin outside of a clinical setting was associated with mental health benefits including decreases in anxiety and depression. The research, which was published September in the journal Frontiers in Psychiatry, studied nearly 3,000 people who reported on their experience taking psilocybin mushrooms. 

To conduct the study, which is reportedly the largest study of psilocybin in a naturalistic (non-clinical) setting, researchers spent two years collecting data from 2,833 participants who planned to take psilocybin for purposes of “self-exploration.” Most participants were college-educated white men in the United States who had previous experience taking psychedelic drugs.

The study participants were asked to fill out five surveys as part of the research. The first survey was completed two weeks prior to the psilocybin experience, which usually consisted of ingesting dried mushrooms, and again the day before the planned psychedelic trip. The remaining surveys were taken one to three days after the experience, two to four weeks after and two to four months after taking the psilocybin. 

After analyzing the data from the surveys, researchers determined that participants reported long-lasting reductions in anxiety, depression, alcohol misuse, neuroticism and burnout. Additionally, the participants reported improvements in cognitive flexibility, emotion regulation, spiritual well-being and extraversion. The new research aims to add to the body of knowledge of what is known about the effects of psilocybin.

In an interview with Taste of Country published on May 24, Grammy Award-nominated country artist Jason “Jelly Roll” DeFord said that he smokes weed to stay away from hard drugs that he’s used in the past—namely opioids and benzodiazepines.

Given his past as an addict and his role in speaking against the use of fentanyl sweeping the country, the interview quickly shifted on the topic of drugs. But Jelly Roll doesn’t see weed the same way as hard drugs which can tear families apart and lead to deadly overdoses.

“I get in trouble for this, all the time, but my stance on marijuana will always be the same: I believe marijuana has helped me in so many regards, with my anxiety,” Jelly Roll told Taste of Country. “This is a hot button topic, but, truly, marijuana has kept me sober.”

The country superstar paused for a moment, then added, “I think a world without weed, Jelly Roll’s drinking codeine and popping Xanax and snorting cocaine again, but a world with weed, I’ll be alright.”

Jelly Roll abandoned hip-hop for a career in country music—which turned out to be a wise and lucrative decision. Jelly Roll’s album Whitsitt Chapel hit number 1 on the Billboard Top Rock Albums chart and number 2 on the Billboard Top Country Albums in 2023. In November 2023, he won the award for New Artist of the Year at the 57th Annual Country Music Association Awards. He’s won three CMT Music Awards and several other accolades.

TMZ reports that Jelly Roll has been a huge voice against fentanyl use and an example for people dealing with drug addiction. Last January, he appeared in front of Congress to back anti-fentanyl legislation called the Fentanyl Eradication and Narcotics Deterrence (FEND) Off Fentanyl Act.

Jelly Roll gave an opening statement at a Senate Banking, Housing, and Urban Affairs Committee hearing about fentanyl awareness and legislative solutions to stop illegal smuggling of fentanyl. “Fentanyl transcends partisanship and ideology…this is a totally different problem,” he started the hearing with in a speech that was described by many as “powerful.”

‘The sad news is that narrative is changing, too, because the statistics say that in all likelihood almost every person in this room has lost a friend, family member of colleague to the disease known as addiction,’ DeFord told the committee chaired by Cleveland Democrat Sherrod Brown. ‘I could sit here and cry for days about the caskets I’ve carried of people I love dearly.’”

His messages about fentanyl and hard drug use, and the potential of replacing them with a less dangerous substance such as pot, have made a lasting impact.

Cannabis for Addiction

Cannabis has been explored for its potential role in fighting addiction of hard drugs. Some studies have focused on CBD for treating addiction disorders, some of which are caused by compulsive cravings, while others focused on THC as well.

While many studies have focused on cannabis to curb opioid use with some looking more broadly at stimulants, new research suggests that it could prove useful for those with crack use disorder (CUD). In fact, the popular non-psychoactive CBD, or cannabidiol, seems to be the key element.

The study, published recently in the International Journal of Mental Health and Addiction, utilized a double-blind randomized clinical trial comparing CBD to three drugs commonly used to treat CUD: fluoxetine, valproic acid and clonazepam. Authors represent a number of Brazilian academic and official institutions, comprising various departments at the University of Brasília, the Brazilian Federal District’s secretary of health and forensic institute and the Federal University of São Paulo.

The research ultimately found that participants who took CBD had better health outcomes and fewer adverse effects compared to those who underwent traditional pharmaceutical options.

In another study published in the journal Addictive Behaviors, researchers found that cannabis is not only widely used to manage stimulant cravings but that it may be an effective strategy to reduce stimulant use.

To further analyze how cannabis use may affect people using stimulant drugs, researchers collected data from three cohorts in Vancouver, Canada: the At-Risk Youth Study (ARYS), the Vancouver Injection Drug Users Study (VIDUS) and the AIDS Care Cohort to Evaluate Exposure to Survival Services (ACCESS).

Researchers used a cross-sectional questionnaire alongside logistic regression models to analyze the relationship between cannabis use to manage stimulant cravings as well as self-reported changes in the frequency of stimulant use. 

Many others say cannabis replaced their daily alcohol use.

The studies seem to back up some of the claims about cannabis and sobriety. Jelly Roll, like country outlaw Willie Nelson, are helping to spread the good word on cannabis to the country music world.

The rising prominence of regular cannabis use over alcohol use is nothing new. 

We’ve witnessed myriad research in recent years showing that states with legal recreational cannabis see decreases in alcohol use, that Gen Z tends to prefer cannabis over alcohol and other reports noting that cannabis has consistently generated more tax revenue than alcohol and cigarettes in states like Colorado and Washington. 

So it’s not necessarily a surprise that, for the first time, the number of Americans who use cannabis on a daily, or near-daily, basis has eclipsed those who drink alcohol at the same frequency. Associated Press first reported on the recent analysis of national survey data, finding that an estimated 17.7 million people reported daily or near-daily cannabis use, compared to 14.7 million daily or near-daily American drinkers.

For comparison, 1992 was the low point for daily cannabis use as less than 1 million people at the time said they used cannabis every day.

Daily Use Among 40% of Cannabis Consumers

According to study author Jonathan Caulkins, who researches cannabis policy at Carnegie Mellon University, alcohol is still more widely used, but 2022 was the first time that the level of cannabis use overtook daily or near-daily drinking.

“A good 40% of current cannabis users are using it daily or near daily, a pattern that is more associated with tobacco use than typical alcohol use,” Caulkins said.

Caulkins’ study, titled “Changes in self-reported cannabis use in the United States from 1979 to 2022,” is based on data from the National Survey on Drug Use and Health and published in the journal Addiction on Wednesday. It notes that there was a 15-fold increase in the per capita rate of reporting daily or near-daily cannabis use from 1992 to 2022, whereas the 1992 survey found 10 times as many daily or near-daily alcohol users compared to cannabis users.

Reflecting alcohol as the more commonly used substance, the study notes that the median drinker reported alcohol use on four to five days in the past month, versus 15 to 16 days of past-month use for cannabis users. Past-month cannabis consumers were almost four times as likely to report daily or near-daily use and 7.4 times more likely to report daily use, according to the study.

A Decades-Long Journey for Cannabis

Of course, this trend is no accident. It’s the product of gradual policy changes, advocacy and broader education surrounding the true nature of cannabis use and cannabis consumers following decades of skewed propaganda and harsh criminalization.

The study notes four major periods of cannabis policy fluctuation in the U.S., starting with liberalization in the ‘70s as 11 states decriminalized or reduced cannabis-related penalties. This is alongside the Shafer Commission report, which countered the popular notion that cannabis users were dangerous, concluding that users tend to be more passive and cannabis does not cause widespread danger to society. It also recommended social measures to curb usage rather than criminalization.

The more conservative policies of the 1980s and early ‘90s followed, with President Reagan and Bush Sr.’s now somewhat infamous War on Drugs in full force. The third major period outlined by the study spans 1993 to 2008, a period of “state-led liberalization” underscored by an increasing recognition of medical cannabis contrary to federal policy.

Finally, we witness the period of “explicit non-interference by the federal government” starting in 2009, with Deputy Attorney General David Ogden’s memo prompting American attorneys not to focus “federal resources in your states on individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of marijuana.”

Just a few years later, Colorado and Washington became the first states to legalize adult-use cannabis.

“There were myriad other changes at the local, state and federal level in both law and policy,” the study notes. “Change has been continual, so these epochs are just signposts, not the only moments of change.”

Weighing Impacts of Daily Cannabis Use Over Daily Alcohol Use

For those who have tried cannabis and who use it routinely, this information may not come as much of a surprise. American attitudes around cannabis have shifted, with the majority routinely sharing they consider cannabis as a safer alternative that alcohol and cigarettes.

Research is also increasingly finding a lack of “hangover” effects in cannabis users, showing no evidence of next-day effects following THC consumption. This, of course, acts in stark contrast to alcohol use, so those who use cannabis frequently arguably have fewer obstacles to navigate surrounding general day-to-day functions. In addition, research is increasingly finding that even chronic pot use has minimal effects on motivation.

Regular cannabis use isn’t without its faults. The Associated Press report includes the perspective of University of Maryland School of Medicine psychiatry professor Dr. David A. Gorelick, who notes that high-frequency cannabis users are more likely to become addicted to cannabis. Gorelick was not involved in the original study.

Some studies have also pointed to increased risk in heart problems among heavy cannabis users (though other studies have suggested the opposite). 

There’s also been a recent influx in studies suggesting that cannabis use, especially surrounding high-potency products, produces greater risk in developing psychosis. While substance abuse disorders indeed carry psychiatric comorbidities, there is limited evidence surrounding how this relationship translates to the general population and how much substance use disorders are driven by such comorbidities. 

A number of studies have combated that narrative with advocates often arguing that touting this relationship between cannabis use and psychosis is simply the newest iteration of “reefer madness” of past years.

Of course, more research is needed to fully determine the health impacts of regular cannabis use — something that the upcoming Schedule III status of cannabis will likely aid in. 

That said, regular alcohol use is known to affect how the brain works over time, damage the heart, increase risk of stroke and high blood pressure and weaken the immune system, leaving people more susceptible to illness. There’s also the toll it takes on the liver and pancreas and its potential to cause several types of cancer.

While cannabis may not be perfect, even your standard “recreational” user is likely to cite a number of medical-specific benefits they enjoy from their use. Many regular cannabis users utilize it as a means to better wellness or to usher in specific symptom relief while also helping to provide a sense of ease and escape from their struggles. 

All to say, research like this often affirms what those in the cannabis community have been saying for years. Perhaps society is finally beginning to catch up.